Drug intelligence / Profile preview

heparin + salbutamol

Development stage
Phase 4
Modality
Small Molecules
Administration
Inhalation
01

Overview

Heparin + salbutamol is a combination therapy involving the co-administration of nebulized heparin and salbutamol (also known as albuterol). Heparin is an anticoagulant that, beyond its blood-thinning properties, exhibits anti-inflammatory effects and can reduce the adherence of bacteria and viruses to bronchial surfaces. Salbutamol is a short-acting beta-2 adrenergic agonist bronchodilator that relaxes airway smooth muscle, improving airflow in conditions like asthma and chronic obstructive pulmonary disease (COPD). The combination has been studied primarily for use in mechanically ventilated patients with acute exacerbations of COPD (AECOPD), where it has shown efficacy in increasing ventilator-free days without increasing bleeding risk. Heparin acts by potentiating antithrombin III activity to inhibit clotting factors, while salbutamol stimulates beta-2 adrenoceptors to induce bronchodilation and also exerts anti-inflammatory effects by inhibiting mast cell degranulation and phospholipase A2 activity[1][5][7].

02

Targets

ATIII (Antithrombin III)ADRB2 (β2)PLA2 (Phospholipase A2 group IID)

Beyond the preview

Go deeper on heparin + salbutamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on heparin + salbutamol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call